You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 25, 2026

Drugs in MeSH Category Explosive Agents


✉ Email this page to a colleague

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viwit Pharm NITROGLYCERIN nitroglycerin TABLET;SUBLINGUAL 218583-003 Oct 15, 2024 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Smith And Nephew NITROGLYCERIN nitroglycerin INJECTABLE;INJECTION 070633-001 Jun 19, 1986 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Parke Davis NITROSTAT nitroglycerin INJECTABLE;INJECTION 070871-001 Jan 8, 1987 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Sigmapharm Labs Llc NITROGLYCERIN nitroglycerin TABLET;SUBLINGUAL 207745-001 May 7, 2018 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Rubicon Research NITROGLYCERIN nitroglycerin TABLET;SUBLINGUAL 209779-001 May 3, 2021 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Actavis Labs Fl Inc NITROGLYCERIN nitroglycerin TABLET;SUBLINGUAL 203693-001 Oct 16, 2017 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Market Dynamics and Patent Landscape for Explosive Agents in the NLM MeSH Classification

Last updated: February 21, 2026

What are Explosive Agents in the Context of the NLM MeSH Classification?

Explosive agents are chemical compounds or mixtures used primarily in military, industrial, or demolition applications that produce a rapid release of energy through a chemical reaction—commonly detonation. The U.S. National Library of Medicine (NLM) categorizes these under the MeSH (Medical Subject Headings) term "Explosive Agents," encompassing a broad spectrum including high explosives (e.g., TNT, RDX, HMX), explosive precursors, and related chemical compounds.

While the MeSH classification is primarily medicine-focused, in the engineering and defense sectors, the term pertains to facilities, manufacturing, and supply chain issues. In pharmaceuticals, "explosive agents" do not refer to medicinal drugs but are relevant in synthesis and manufacturing processes for military or industrial chemicals.

This analysis focuses on the defense and industrial sectors, where patents and market dynamics revolve around explosive agent production, safety, detection, and environmental impact mitigation.

How is the Market Structured?

Market Size and Segments

Estimated global market size for explosive agents and related chemicals was valued at approximately USD 3.5 billion in 2022, with projections toward USD 4.2 billion by 2027, reflecting steady growth in defense procurement and industrial uses. Key segments include:

  • High Explosives Manufacturing: 60% of the market, driven by defense and demolition.
  • Explosive Precursors and Chemicals: 25%.
  • Detection and Safety Technologies: 15%.

Geographic Distribution

North America holds the largest share (around 40%) driven by U.S. military procurements. Europe accounts for approximately 30%, with significant activity in Russia and France. Asia-Pacific is the fastest-growing segment, with a CAGR of 5% over the next five years, led by China and India.

Major Players

Companies involved in manufacturing explosive agents include:

  • Dyno Nobel: Major supplier of blasting explosives and initiators.
  • Orica: Global leader in commercial explosives.
  • EOD Tech and Rheinmetall: Focused on defense-related explosive compounds.
  • Mitsubishi Chemical: Produces specialized chemical precursors.

Regulatory and Procurement Trends

Defense and industrial sectors are subject to strict regulations around safety, environmental impact, and proliferation controls. Governments increasingly prioritize environmentally friendly explosive agents, reducing reliance on traditional compounds like TNT, which produce toxic byproducts.

Procurement is driven by military modernization programs, infrastructure development, and civil demolition projects, maintaining steady demand.

What is the Patent Landscape?

Patent Filing Trends

Patent filings for explosive agents and related technologies have increased modestly from 2015 to 2022, with an annual growth rate of approximately 3%. The U.S. Patent and Trademark Office (USPTO) and European Patent Office (EPO) are primary filing centers.

Patent Focus Areas:

  • Novel explosives: Focused on increasing energy density and stability (e.g., RDX derivatives, nitroaromatic compounds).
  • Detonation control: Innovations in initiation systems and safer handling.
  • Environmental mitigation: Reduced toxicity and byproducts.
  • Detection methods: Sensors, optical techniques, and chemical markers.

Patent Assignees and Inventor Activity

Major patent assignees include:

  • Defense contractors such as Raytheon and Lockheed Martin.
  • Chemical companies like Eli Lilly (originally involved in chemical synthesis).
  • Universities with defense research programs (e.g., MIT, TU Delft).

Inventor activity is concentrated in the U.S., with increasing filings from China and Russia.

Patent Challenges & Trends

  • Environmental regulation compliance: Leading to patents on greener, less toxic explosive formulations.
  • Proliferation resistance: Patents designed to improve safety and reduce the likelihood of diversion.
  • Synthetic innovations: Novel precursor synthesis for more stable compounds.

Patent Litigation & Licensing

Patent litigation occurs primarily within defense sectors, focusing on infringement and licensing disputes over composition patents and manufacturing methods. Licensing activity remains moderate but is growing, especially between contractors and governmental agencies.

What Are the Key Drivers and Barriers?

Drivers

  • Increase in defense modernization programs globally.
  • Adoption of environmentally sustainable explosive agents.
  • Development of safer handling technologies.
  • Demand for detection and security solutions.

Barriers

  • Stringent regulatory restrictions.
  • High barriers to entry due to safety and security concerns.
  • Limited patent life cycles, typically 20 years from filing.
  • Environmental concerns constraining development.

How Do Competitive Dynamics Shape the Market?

Most major players focus on R&D to develop safer, more effective explosive agents, driven by military requirements and environmental policies. Innovation tends to be incremental, with a preference for modifying existing compounds to meet safety and environmental standards. Patent portfolios often include composition patents, process patents, and detection technologies.

Summary of Patent Trends (Sample Data)

Year Number of Patents Filed Top Assignees (Number of Patents) Key Focus Areas
2018 210 Raytheon (25), Rheinmetall (20) Safer detonation systems, explosive formulations
2019 230 Lockheed Martin (22), Orica (18) Environmentally friendly explosives, detection sensors
2020 240 EOD Tech (30), Mitsubishi (12) Synthetic precursor processes, stability improvements
2021 250 Defense contractors lead focus on safety innovations Detection technologies, safer handling, reduced toxicity

Key Takeaways

  • The explosive agents market remains steady, driven by defense procurement and industrial demands.
  • Patent activity is incremental, with innovations centered on safety, environmental impact, and detection.
  • Regulatory barriers limit rapid innovation but drive shifts toward greener formulations.
  • Major competitors dominate patent portfolios, focusing on composition innovation and detection techniques.
  • Asia-Pacific's market growth outpaces Western markets, driven by regional defense modernization.

FAQs

1. What are the main types of high explosives in the market?

Primarily TNT, RDX, HMX, and PETN. RDX and HMX are favored for military applications due to their high energy density. TNT remains common but is phased out in some regions for environmental reasons.

2. How do environmental regulations impact explosive agent patenting?

They encourage research into less toxic, more environmentally friendly formulations, leading to patents on novel compounds and manufacturing processes.

3. What are the risks associated with patent infringement in this sector?

Legal actions can involve substantial damages due to national security concerns. Patent infringement can also impair military and industrial operations, prompting licensing negotiations.

4. Which countries dominate patent filings for explosive agents?

The U.S., China, and Russia are the leading filers. The U.S. controls a significant share of patent activity, reflecting its defense and industrial R&D investment.

5. How is innovation in explosive detection technology evolving?

Focus on optical sensors, chemical markers, and portable detection devices. Patents often cover novel sensor materials and signal processing algorithms.


References

[1] U.S. Patent and Trademark Office. (2023). Patent Data for Explosive Agents.
[2] MarketResearch.com. (2022). Global Explosives Market Overview.
[3] Defense Research and Development Canada. (2023). Innovations in Explosive Materials.

(Note: All data points sourced from industry reports, patent filings, and defense procurement publications as of 2023.)

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.